R&D News | pharmaphorum

News

Pfizer bulks up in RSV with $525m takeover of ReViral

Pfizer is looking to follow its vaccine/oral antiviral combination that has proved so profitable in COVID-19 with a similar approach in

News

Merck turns to cardiovascular pipeline for its post-Keytruda...

For some years industry observers have been asking what Merck & Co can do to reduce its reliance on blockbuster cancer immunotherapy Keytruda.

News

Bluebird sheds a third of its workforce to cut costs

Gene therapy specialist bluebird bio has said 30% of its workforce will lose their jobs, in a bid to conserve cash as it tried to get its lead programmes over the finish line.

News

Cytokinetics' heart drug omecamtiv strikes out in heart fail...

Cytokinetics' hopes of resurrecting cardiac myosin activator omecamtiv mecarbil have suffered another setback, after the drug failed to show a benefit in a phase 3 heart failure study.

News

Closeup of X-ray photography of human brain

Study uncovers new Alzheimer's genes, links to immune disrup...

The largest-ever study of genetics in Alzheimer's disease patients has identified 42 new genes that appear to be linked to the neurodegenerative disorder.

News

Hand in glove holding Petri plate with bacteria Steptococcus Phaemolifticus G, Streptococcus Agalactiae, Streptococcus Phaemolifticus

Pharma-backed antibiotic fund makes first investments

Two years after it was first proposed and a year after it officially launched, the pharma-backed AMR Action Fund has made its first investments in companies trying to tackle the pressing pr

Pfizer bulks up in RSV with $525m takeover of ReViral

Merck turns to cardiovascular pipeline for its post-Keytruda...

Bluebird sheds a third of its workforce to cut costs

Cytokinetics' heart drug omecamtiv strikes out in heart fail...

Study uncovers new Alzheimer's genes, links to immune disrup...

Pharma-backed antibiotic fund makes first investments

Five indications added to Pharmacy First prescribing scheme

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks